Navigation Links
Pharmacopeia Announces Positive Results from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
Date:9/12/2007

Pharmacopeia Elects to Expand Study to Include 1,000 mg Dose

PRINCETON, N.J., Sept. 12 /PRNewswire-FirstCall/ -- Pharmacopeia (Nasdaq: PCOP), an innovator in the discovery and development of novel small molecule therapeutics, today announced that based on initial results from the Company's Phase 1 multiple ascending dose (MAD) study of its lead internal product candidate, PS433540 (DARA), no safety or tolerability issues were observed with any of the doses under evaluation. As a result, the study will be expanded to include a 1,000 mg dose. This study designed to evaluate 14 days of daily dosing in healthy volunteers, has already completed evaluation of 50, 100, 250 and 500 mg doses of PS433540. The Company expects to report findings from the 1,000 mg dose later this year.

"The purpose of a multiple ascending dose study of this nature is to determine the maximally tolerated dose of a compound in healthy volunteers. Since we did not reach that threshold with this study's original four doses, we've decided to expand the trial and evaluate this fifth dose level," stated Rene Belder, M.D., Pharmacopeia's Vice President of Clinical and Regulatory Affairs. "The fact that this compound appears safe and well tolerated at a wide dose range will provide added dosing flexibility for subsequent clinical trials."

In addition, results from the initial Phase 1 trial of PS433540, a single ascending dose (SAD) study, indicated that the compound was well tolerated at all six doses administered, while also suggesting that PS433540 possesses a half-life that is consistent with once daily oral administration.

PS433540 is a dual-acting angiotensin (AII) and endothelin (ET1) receptor antagonist that is being dev
'/>"/>

SOURCE Pharmacopeia
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Pharmacopeia Announces Positive Results from Initial DARA Clinical Trial
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Sygnis Pharma AG announces date for presentation of clinical results
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA ) today ... Science Firm of the Year by the Tech Council of ... the TCM,s 25 th Annual Tech Awards Celebration held ... Celebration recognizes the leaders and innovators in the technology and ... the surrounding regions. "We are deeply honored ...
(Date:5/23/2013)... y PARÍS, 24 de mayo de 2013 /PRNewswire/ ... destacado desarrollador y fabricante de herramientas de precisión ... y tratamiento de la enfermedad vascular periférica y ... ADVISE ( Ad enosine V asodilator ... II durante la sesión de ensayo clínico hot ...
(Date:5/23/2013)... May 23, 2013 Neurocrine Biosciences, Inc. (Nasdaq: ... , President and Chief Executive Officer of Neurocrine Biosciences, ... Annual dbAccess Health Care Conference in Boston.   ... 11:20 a.m. Eastern Time / 8:20 a.m. Pacific Time.  The ... Company,s website at http://www.neurocrine.com . If ...
Breaking Medicine Technology:Vanda Pharmaceuticals Named the 2013 Life Science Firm of the Year by the Tech Council of Maryland 2Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 2Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 3Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 4Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 5Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 6
... FOREST, Ill., Sept. 6, 2011 Hospira, Inc. ... in generic injectable pharmaceuticals, today announced positive results from ... erythropoietin (EPO) in patients with renal (kidney) dysfunction who ... equal pharmacokinetics, or blood level and distribution in the ...
... 2011 Johnson & Johnson (NYSE: JNJ ) ... Tuesday, September 13 th , at the Grand Hyatt New ... New York, NY.  Dominic Caruso, Vice President, Finance and Chief ... the company in a session scheduled at 10:20 a.m. (Eastern). ...
Cached Medicine Technology:Hospira Announces Positive Results From Phase I U.S. Clinical Trial of Biosimilar Erythropoietin in Renal Patients 2Hospira Announces Positive Results From Phase I U.S. Clinical Trial of Biosimilar Erythropoietin in Renal Patients 3
(Date:5/23/2013)... is associated with poor outcomes in hospitalized patients, and ... is a common practice in hospitals. But the recent ... shows harms associated with the use of IIT, according ... Committee in a new evidence-based paper published today online ... , "Clinicians caring for hospitalized patients must keep the ...
(Date:5/23/2013)... 2013 Internationally recognized as one of ... for over 29 years, Coach Nick Saviano’s ... WTA players, Grand Slam winners, World #1’s; Junior Wimbledon, ... USTA National Junior Champions, 8 Foreign National Junior Champions ... Cup, Orange Bowl and Eddie Herr winners - and ...
(Date:5/23/2013)... (PRWEB) May 23, 2013 Whether working ... Operations Forces and law enforcement need an added layer ... Security Enhancer, Night VISER , is an effective ... motion sensing system to increase border and perimeter security. ... VISER have more than tripled over the past three ...
(Date:5/23/2013)... UNITED KINGDOM (PRWEB) May 24, 2013 ... by A.L. Hodkin, A.F. Huxley and B. Katz in ... to account for the role of sodium and potassium ... electrophysiological techniques and the data acquisition techniques have known ... Yves Pichon wants to give an account of ...
(Date:5/23/2013)... In his pulse-quickening novel, “The AIDS Covenant” (published by AuthorHouse), ... government?” , In the “The AIDS Covenant,” readers meet Dr. ... ’s Heathrow Airport. His American colleague, Alan Milner of BAYMED ... arrive at his Sierra Nevada ski-lodge. , ... the government’s report. When Alan learns that Owen was killed ...
Breaking Medicine News(10 mins):Health News:ACP issues recommendations for management of high blood glucose in hospitalized patients 2Health News:Internationally Respected Tennis Coach, Nick Saviano Opens Summer Training Registration 2Health News:Lighting Up the Night: ARA Announces Record Sales of Its Night VISER System 2Health News:Lighting Up the Night: ARA Announces Record Sales of Its Night VISER System 3Health News:Yves Pichon’s New Book Presents Latest Neurophysiological Discoveries 2Health News:Yves Pichon’s New Book Presents Latest Neurophysiological Discoveries 3Health News:New Book “The AIDS Covenant” by Roy Harris Delivers Intriguing, Captivating Story 2
... The National Commander of the Disabled American Veterans begins ... support for budget reform legislation to ensure sufficient, timely ... is urging them to reject a contentious proposal that ... conditions from the government,s side of the ledger to ...
... cranberriesand not the acidity of cranberry juice, as previously ... line the urinary tract, as documented in a report ... peer-reviewed journal published by Mary Ann Liebert, Inc. ( ... www.liebertpub.com/jmf , Urinary tract infections (UTIs) burden ...
... March 9 Quest Diagnostics Incorporated (NYSE: ... information and services, announced that it is scheduled to ... on Tuesday, March 10, 2009. The Quest Diagnostics ... Time.During the conference, the company will reaffirm its 2009 ...
... Sport Beans and Nike Motivate College Students to Complete ... SpringNEW YORK, March 9 American Collegiate Intramural Sports ... corporate sponsors are joining together to launch ACIS Fitness ... college marketing platform is aimed at motivating the 2.7 ...
... Japanese scientists will arrive at the University of Houston ... that promises to deliver more comprehensive and accurate insights ... of current technologies. , In April, Mikio Kubota of ... join the research team at UH,s Biomedical Imaging Lab. ...
... President Obama signed an executive order ... stem cell research, overturning limits on federal funding for ... President & CEO of Americans United for Life responded, ... past. Millions of dollars have been spent on ...
Cached Medicine News:Health News:Disabled Veterans Leader Presses Issues with Key Lawmakers 2Health News:New research reveals how cranberry products prevent urinary tract infections 2Health News:Quest Diagnostics to Speak at Barclays Capital Global Healthcare Conference 2Health News:ACIS Fitness Challenges Launch Across 200 Colleges Nationwide 2Health News:UH research team developing new noninvasive brain-mapping technology 2Health News:UH research team developing new noninvasive brain-mapping technology 3Health News:UH research team developing new noninvasive brain-mapping technology 4Health News:Americans United for Life: Obama Administration Stem Cell Policy an Anti-Life Waste of Tax Dollars 2
... tissue, mucous, and other body fluids -- ... as box joints and tubing -- while ... Original is strong enough for the toughest ... everyday. Prolong the life of your instruments ...
... MPD is the highly ... surgical instruments manually or with an ... enough to remove blood and organic ... cleaning. Use MPD to clean surgical ...
... Features you need for critical patients ... blood,pressures, a comprehensive calculations package and ... that you can transport with your ... frequently used functions which means ...
The ApexPro CH is operational within the WMTS. It offers operating performance, up to 240 WMTS channels, and up to 120 hours of battery life....
Medicine Products: